<PAPER><mode2 name='PMC4448151' hasDoc='yes' version='597'></mode2><article xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Alzheimers Res Ther</journal-id><journal-id journal-id-type='iso-abbrev'>Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &amp; Therapy</journal-title></journal-title-group><issn pub-type='epub'>1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>4448151</article-id><article-id pub-id-type='publisher-id'>128</article-id><article-id pub-id-type='doi'>10.1186/s13195-015-0128-z</article-id><article-categories><subj-group subj-group-type='heading'><subject>Review</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>Comprehensive treatment of dementia with Lewy bodies</s></article-title></title-group><contrib-group><contrib contrib-type='author' corresp='yes'><name><surname>Boot</surname><given-names>Brendon P</given-names></name><address><email>bboot@partners.org</email></address><xref rid='Aff1' ref-type='aff'></xref><xref rid='Aff2' ref-type='aff'></xref></contrib><aff id='Aff1'><label></label>Department of Neurology, Brigham and Women’s Hospital, 221 Longwood Avenue, Boston, MA 02115 USA </aff><aff id='Aff2'><label></label>Harvard Medical School, 25 Shattuck Street, Boston, MA 02115 USA </aff></contrib-group><pub-date pub-type='epub'><day>29</day><month>5</month><year>2015</year></pub-date><pub-date pub-type='pmc-release'><day>29</day><month>5</month><year>2015</year></pub-date><pub-date pub-type='collection'><year>2015</year></pub-date><volume>7</volume><issue>1</issue><elocation-id>45</elocation-id><permissions><copyright-statement>© Boot; licensee BioMed Central. 2015</copyright-statement><license license-type='open-access'><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/licenses/by/4.0'>http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/publicdomain/zero/1.0/'>http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id='Abs1'><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Dementia with Lewy bodies is an under-recognized disease; it is responsible for up to 20 % of all dementia cases.</s><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Accurate diagnosis is essential because the management of dementia with Lewy bodies is more complex than many neurodegenerative diseases.</s><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This is because alpha-synuclein, the pathological protein responsible for dementia with Lewy bodies (and Parkinson’s disease), produces symptoms in multiple domains.</s><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> By dividing the symptoms into cognitive, neuropsychiatric, movement, autonomic, and sleep categories, a comprehensive treatment strategy can be achieved.</s><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Management decisions are complex, since the treatment of one set of symptoms can cause complications in other symptom domains.</s><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Nevertheless, a comprehensive treatment program can greatly improve the patient’s quality of life, but does not alter the progression of disease.</s><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Cholinesterase inhibitors are effective for cognitive and neuropsychiatric symptoms; rivastigmine has the widest evidence base.</s><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Special care needs to be taken to avoid potentially fatal idiopathic reactions to neuroleptic medications; these should be used for short periods only when absolutely necessary and when alternative treatments have failed.</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Pimavanserin, a selective serotonin 5-HT2A inverse agonist, holds promise as an alternative therapy for synuclein-associated psychosis.</s><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Levodopa/carbidopa treatment of parkinsonism is often limited by dopa-induced exacerbations of neuropsychiatric and cognitive symptoms.</s><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Autonomic symptoms are under-recognized complications of synucleinopathy.</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Constipation, urinary symptoms and postural hypotension respond to standard medications.</s><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Rapid eye movement sleep behavior disorder is highly specific (98 %) to the synucleinopathies.</s><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Nonpharmacological treatments, melatonin and clonazepam are all effective.</s></p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type='introduction' id='Sec1'><title>Introduction</title><p><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Dementia with Lewy bodies (DLB) is an under-recognized disease.</s><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The diagnostic criteria have low sensitivity (12 to 32 %) and high specificity (&gt;95 %) [<xref rid='CR1' ref-type='bibr'>1</xref>], so many cases are not diagnosed.</s><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Therefore, meta-analytic studies suggesting that DLB accounts for 4 % of dementia diagnoses [<xref rid='CR2' ref-type='bibr'>2</xref>] underestimate the true prevalence [<xref rid='CR3' ref-type='bibr'>3</xref>], which may be closer to 20 % of dementia [<xref rid='CR4' ref-type='bibr'>4</xref>, <xref rid='CR5' ref-type='bibr'>5</xref>].</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Parkinson’s disease dementia (PDD) accounts for a further 3 to 5 % of dementia cases [<xref rid='CR5' ref-type='bibr'>5</xref>, <xref rid='CR6' ref-type='bibr'>6</xref>].</s><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Both DLB and PDD are due to the pathological accumulation of alpha-synuclein, but patients with parkinsonism for 1 year prior to cognitive decline are classified as PDD [<xref rid='CR4' ref-type='bibr'>4</xref>].</s><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Cognitive decline and parkinsonism are insidious, so the distinction can be difficult to draw and may be influenced by the subspecialty interest of the diagnosing neurologist (for example, movement disorder versus behavioral neurology) [<xref rid='CR1' ref-type='bibr'>1</xref>, <xref rid='CR7' ref-type='bibr'>7</xref>].</s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Data on the relative frequency of DLB and PDD may be similarly affected by this subspecialty referral pattern.</s><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Whether or not the distinction has treatment implications is difficult to determine.</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> This review highlights the distinction only where clinically relevant differences in outcomes have been noted.</s><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Restricting this review only to evidence-based treatments would mean that it could not be comprehensive, since many treatments have not been studied in DLB or PDD populations.</s><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In these instances, evidence from Parkinson’s disease (PD) studies is used to guide clinical recommendations.</s></p><p><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The management of DLB is replete with quandaries: in choosing to treat one symptom, we often produce complications in other facets of the disease.</s><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> For example, dopamine replacement for motor symptoms frequently exacerbates a patient’s neuropsychiatric symptoms, antipsychotic treatment of hallucinations risks a potentially fatal adverse reaction, and cholinesterase inhibitor treatment of cognitive symptoms can complicate cardiac and gastrointestinal dysautonomia.</s><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> These quandaries make the treatment of DLB challenging, yet just as rewarding as navigating between Scylla and Charybdis.</s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The side-effect proclivity applies to medications prescribed by other physicians, so it is essential to rationalize treatment and to communicate with other care providers about the complexities of the disease.</s><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> An understanding of the pervasive effects of alpha-synuclein can also assist the physician to make sense of nonspecific or vague complaints, particularly when advanced disease impairs a patient’s ability to communicate.</s><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> For example, a feeling of general malaise or lethargy can reflect orthostatic hypotension, a common and under-recognized feature of the disease.</s></p><p><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Many symptoms of DLB are noncognitive in nature, and many are under-recognized [<xref rid='CR8' ref-type='bibr'>8</xref>–<xref rid='CR10' ref-type='bibr'>10</xref>].</s><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> It can be helpful to divide the array of symptoms into five symptom categories: cognitive, neuropsychiatric, movement, autonomic, and sleep.</s><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Patients often view DLB as a purely cognitive disease, and consequently will not volunteer noncognitive symptoms since they do not believe they are a consequence of the disease.</s><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Directed questions in each of the five categories can form the basis of a comprehensive treatment strategy that can improve the patient’s quality of life [<xref rid='CR11' ref-type='bibr'>11</xref>].</s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The disease course can be rapid, although prognosis varies between individuals.</s><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In one study, life expectancy at diagnosis is 2.3 years shorter for DLB compared with Alzheimer’s disease [<xref rid='CR10' ref-type='bibr'>10</xref>].</s></p></sec><sec id='Sec2'><title>Cognitive symptoms</title><p><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>DLB-associated deficits in attention, executive function, and visuospatial ability respond well to cholinesterase inhibitor treatment [<xref rid='CR12' ref-type='bibr'>12</xref>–<xref rid='CR14' ref-type='bibr'>14</xref>].</s><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In meta-analyses, the standardized mean treatment effects are 0.34 for cognition and 0.20 on behavioral and functional measures [<xref rid='CR13' ref-type='bibr'>13</xref>], although most of the source data are from PDD patients.</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> These effects compare favorably with cholinesterase inhibitor treatment of Alzheimer’s disease [<xref rid='CR15' ref-type='bibr'>15</xref>], because the targets of therapy are relatively preserved in DLB.</s><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Compared with Alzheimer’s patients, DLB patients have relatively little neuronal loss but profound cholinergic dysfunction [<xref rid='CR5' ref-type='bibr'>5</xref>, <xref rid='CR16' ref-type='bibr'>16</xref>].</s><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The characteristic fluctuations in cognition in DLB are difficult to manage; they may have multiple contributing causes [<xref rid='CR17' ref-type='bibr'>17</xref>].</s><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Cholinesterase inhibitor treatment is associated with reduced mortality; mortality odds ratios in treatment trials are 0.28 (<italic>P</italic> = 0.03) despite increases in adverse events on therapy (odds ratio 1.64, <italic>P</italic> = 0.0003) [<xref rid='CR14' ref-type='bibr'>14</xref>].</s></p><p><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>There are no head-to-head trials comparing efficacy of the cholinesterase inhibitors in DLB or PDD, but rivastigmine has the widest evidence base [<xref rid='CR12' ref-type='bibr'>12</xref>, <xref rid='CR18' ref-type='bibr'>18</xref>, <xref rid='CR19' ref-type='bibr'>19</xref>].</s><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A Movement Disorder Society evidence-based review concluded that rivastigmine is effective in PDD, but that the data for other cholinesterase inhibitors and memantine are inconclusive [<xref rid='CR20' ref-type='bibr'>20</xref>].</s><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Special care is needed when starting cholinesterase inhibitors in patients with DLB because of frequent disease-associated autonomic dysfunction [<xref rid='CR21' ref-type='bibr'>21</xref>].</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Cardiac denervation [<xref rid='CR22' ref-type='bibr'>22</xref>] might increase the risk of symptomatic bradycardia [<xref rid='CR13' ref-type='bibr'>13</xref>, <xref rid='CR23' ref-type='bibr'>23</xref>], or QT prolongation.</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Gastrointestinal dysautonomia [<xref rid='CR24' ref-type='bibr'>24</xref>, <xref rid='CR25' ref-type='bibr'>25</xref>] means patients may be more at risk for the common cholinesterase inhibitor side effects of nausea, vomiting, diarrhea, anorexia, and weight loss [<xref rid='CR13' ref-type='bibr'>13</xref>, <xref rid='CR26' ref-type='bibr'>26</xref>].</s><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> To treat these, the clinician should eschew antagonists of dopamine, acetylcholine, or histamine in favor of 5HT-3 receptor antagonists such as ondansetron or granisetron.</s><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Rivastigmine has a transdermal formulation with fewer gastrointestinal side effects.</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> DLB patients frequently have disordered sleep and so may be more likely to experience the vivid dreams that are an under-recognized side effect of cholinesterase inhibitors.</s><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> These dreams can be limited by avoiding night-time doses; for cholinesterase inhibitors that require twice-daily dosing, the second dose may be given in the afternoon.</s></p><p><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Only one of four trials of memantine in DLB/PD/PDD found significant effects in the primary outcome [<xref rid='CR27' ref-type='bibr'>27</xref>].</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The results may be driven by data from PDD rather than DLB subjects, and may only be present with concurrent cholinesterase inhibitor treatment [<xref rid='CR27' ref-type='bibr'>27</xref>, <xref rid='CR28' ref-type='bibr'>28</xref>].</s><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Atomexetine [<xref rid='CR29' ref-type='bibr'>29</xref>], rasagiline [<xref rid='CR30' ref-type='bibr'>30</xref>] and levodopa [<xref rid='CR31' ref-type='bibr'>31</xref>, <xref rid='CR32' ref-type='bibr'>32</xref>] have variable effects on cognition in PD/PDD populations [<xref rid='CR33' ref-type='bibr'>33</xref>].</s></p></sec><sec id='Sec3'><title>Neuropsychiatric symptoms</title><sec id='Sec4'><title>Anxiety and depression</title><p><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Anxiety and depression are common in DLB; they affect 27 % and 59 % of cases, respectively [<xref rid='CR10' ref-type='bibr'>10</xref>].</s><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Like many nonmotor symptoms of synucleinopathy, anxiety and depression can predate the onset of parkinsonism and dementia by decades [<xref rid='CR10' ref-type='bibr'>10</xref>, <xref rid='CR21' ref-type='bibr'>21</xref>, <xref rid='CR34' ref-type='bibr'>34</xref>], possibly due to early pathology in serotonergic projection cells of the dorsal raphe [<xref rid='CR35' ref-type='bibr'>35</xref>, <xref rid='CR36' ref-type='bibr'>36</xref>].</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Incipient synucleinopathy should therefore be considered in the differential diagnosis of late-onset anxiety and depression, particularly in patients without an obvious precipitant and/or subtle parkinsonism [<xref rid='CR37' ref-type='bibr'>37</xref>, <xref rid='CR38' ref-type='bibr'>38</xref>].</s></p><p><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>There are no controlled trials of treatments for anxiety in DLB or PDD [<xref rid='CR33' ref-type='bibr'>33</xref>].</s><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Depression was one of four neuropsychiatric symptoms in a composite measure that improved in trials of rivastigmine [<xref rid='CR39' ref-type='bibr'>39</xref>] and olanzapine [<xref rid='CR27' ref-type='bibr'>27</xref>, <xref rid='CR40' ref-type='bibr'>40</xref>].</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A single, uncontrolled trial of citalopram and risperidone in 31 patients found no improvement for either drug after 12 weeks [<xref rid='CR41' ref-type='bibr'>41</xref>].</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Otherwise, there is a paucity of evidence in the treatment of depression in DLB.</s><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Serotonin and serotonin/norepinephrine reuptake inhibitor antidepressants have mixed results in the treatment of PD-related depression [<xref rid='CR20' ref-type='bibr'>20</xref>, <xref rid='CR42' ref-type='bibr'>42</xref>, <xref rid='CR43' ref-type='bibr'>43</xref>].</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Electroconvulsive treatment and transcranial magnetic stimulation are both effective in DLB [<xref rid='CR44' ref-type='bibr'>44</xref>, <xref rid='CR45' ref-type='bibr'>45</xref>].</s></p></sec><sec id='Sec5'><title>Hallucinations and delusions</title><p><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Hallucinations occur in 60 to 70 % of DLB patients [<xref rid='CR8' ref-type='bibr'>8</xref>].</s><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Commonly, they begin in the first 2 or 3 years of the disease whereas they are a late phenomenon in Alzheimer’s disease [<xref rid='CR46' ref-type='bibr'>46</xref>].</s><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> There may also be qualitative differences.</s><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In Alzheimer’s disease, hallucinations generally have a threatening or fearful quality [<xref rid='CR47' ref-type='bibr'>47</xref>].</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> They are often accompanied by delusions of suspicion [<xref rid='CR47' ref-type='bibr'>47</xref>].</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In contrast, the hallucinations in DLB are often (but not always) nonthreatening misperceptions of ambiguous stimuli.</s><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> For example, a patient may misinterpret a shadow to be a person or an animal.</s><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Tests of these misperceptions, termed pareidolias, accurately differentiate DLB from Alzheimer’s disease [<xref rid='CR48' ref-type='bibr'>48</xref>].</s><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Electing not to treat these symptoms is often appropriate, but cholinesterase inhibitor therapy is safe and effective [<xref rid='CR39' ref-type='bibr'>39</xref>].</s><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In one study of PDD, more than 90 % of patients reported reduced visual hallucinations with cholinesterase inhibitor use [<xref rid='CR12' ref-type='bibr'>12</xref>].</s><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The hallucinations can be minimized by regular vision correction and a bright light or no light policy, whilst minimizing the risk of falls.</s><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Medications that can exacerbate neuropsychiatric symptoms in DLB should also be stopped.</s><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> These include anticholinergic medications, amantadine, dopamine agonists, monoamine oxidase inhibitors, catechol-<italic>O</italic>-methyl transferase inhibitors, and levodopa, bearing in mind that abrupt cessation can trigger the neuroleptic malignant syndrome [<xref rid='CR49' ref-type='bibr'>49</xref>].</s></p><p><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>The most fraught decision in the management of DLB relates to the use of antipsychotic medications.</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In Alzheimer’s disease and all-cause dementia studies, antipsychotic medications are rarely effective at reducing symptoms [<xref rid='CR50' ref-type='bibr'>50</xref>] and they increase the risk of stroke and sudden cardiac death by at least 50 % [<xref rid='CR51' ref-type='bibr'>51</xref>, <xref rid='CR52' ref-type='bibr'>52</xref>].</s><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Ceasing these medications decreases the risk of death by the same amount [<xref rid='CR53' ref-type='bibr'>53</xref>].</s><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The latter study counters the idea that the antipsychotic-associated mortality is due to confounding by indication.</s><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> This theory states that end-stage dementia causes increased mortality and also causes the prescription of antipsychotics.</s><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Data from these pivotal studies led to a US Food and Drug Administration black-box warning for antipsychotic medication use in dementia and a substantial change in prescribing practice.</s></p><p><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>A major factor in the success or otherwise of treatment trials of antipsychotic medications in DLB and other dementia relates to the target symptoms.</s><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Hallucinations and delusions are more likely to respond to these medications than behavioral disturbance, as described below.</s><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Physicians should reserve the use of neuroleptics for symptoms likely to respond to their use, after focused behavioral interventions have been attempted.</s><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> There is ample evidence of efficacy for these behavioral interventions [<xref rid='CR54' ref-type='bibr'>54</xref>], but limited funds for implementation.</s><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Gitlin and colleagues provide an excellent description of such a program [<xref rid='CR55' ref-type='bibr'>55</xref>].</s></p><p><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>A continued role for antipsychotic treatment remains for the short-term treatment of subjects at risk of harm due to their psychosis [<xref rid='CR47' ref-type='bibr'>47</xref>].</s><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Higher scores on the Neuropsychiatric Inventory may indicate a patient is more likely to respond to the treatment, particularly if the findings are within the domains most amenable to treatment with neuroleptic medication (see discussion below) [<xref rid='CR56' ref-type='bibr'>56</xref>].</s></p><p><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>DLB patients are particularly at risk of antipsychotic medication morbidity and mortality.</s><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Severe neuroleptic sensitivity occurs in 30 to 50 % of patients [<xref rid='CR57' ref-type='bibr'>57</xref>].</s><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Typical antipsychotics (for example, haloperidol) are best avoided [<xref rid='CR57' ref-type='bibr'>57</xref>], but reactions can occur after any neuroleptic and no differences in mortality were found between the atypical antipsychotics in all-dementia clinical trials [<xref rid='CR50' ref-type='bibr'>50</xref>].</s><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Profound sedation, confusion, exacerbations of parkinsonism, rigidity, dysautonomia, and death can occur [<xref rid='CR4' ref-type='bibr'>4</xref>, <xref rid='CR16' ref-type='bibr'>16</xref>, <xref rid='CR57' ref-type='bibr'>57</xref>, <xref rid='CR58' ref-type='bibr'>58</xref>] even after a single dose [<xref rid='CR57' ref-type='bibr'>57</xref>, <xref rid='CR59' ref-type='bibr'>59</xref>, <xref rid='CR60' ref-type='bibr'>60</xref>].</s><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> These effects are associated with a threefold increase in stroke occurrence and a twofold to fourfold increase in the rate of cognitive decline [<xref rid='CR50' ref-type='bibr'>50</xref>, <xref rid='CR53' ref-type='bibr'>53</xref>].</s><s sid='97'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> There is also evidence to the contrary, however.</s><s sid='98'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Antipsychotic medications have been well tolerated in DLB trials [<xref rid='CR61' ref-type='bibr'>61</xref>, <xref rid='CR62' ref-type='bibr'>62</xref>], and a large observational study that controlled for cardiovascular risk and psychosis severity found no increase in mortality amongst Alzheimer’s disease patients [<xref rid='CR63' ref-type='bibr'>63</xref>].</s><s sid='99'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Irrespective of the controversy over the degree of risk, the large placebo response seen in trials of antipsychotics [<xref rid='CR27' ref-type='bibr'>27</xref>, <xref rid='CR50' ref-type='bibr'>50</xref>] and the data showing improved survival for those taken off long-term antipsychotics treatment [<xref rid='CR53' ref-type='bibr'>53</xref>] dictate that all new prescriptions of antipsychotics should include a programmed trial of cessation [<xref rid='CR64' ref-type='bibr'>64</xref>].</s></p><p><s sid='100'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1>The choice of which antipsychotic to use is also a vexed question.</s><s sid='101'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Quetiapine and clozapine are equally effective in head-to-head PDD trials [<xref rid='CR49' ref-type='bibr'>49</xref>, <xref rid='CR65' ref-type='bibr'>65</xref>], although other data show mixed results for quetiapine in underpowered trials of DLB/PDD [<xref rid='CR20' ref-type='bibr'>20</xref>, <xref rid='CR61' ref-type='bibr'>61</xref>, <xref rid='CR62' ref-type='bibr'>62</xref>, <xref rid='CR66' ref-type='bibr'>66</xref>, <xref rid='CR67' ref-type='bibr'>67</xref>].</s><s sid='102'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Despite the paucity of evidence for its efficacy, many clinicians use quetiapine, reserving clozapine for second-line or third-line treatment because of its potential to cause agranulocytosis [<xref rid='CR68' ref-type='bibr'>68</xref>–<xref rid='CR72' ref-type='bibr'>72</xref>].</s><s sid='103'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> More data are sorely needed to inform antipsychotic medication choice in DLB.</s><s sid='104'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> In the interim, it is reasonable to select antipsychotic medications on the basis of their side-effect profiles.</s><s sid='105'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Patients at risk for diabetes or hyperlipidemia should avoid quetiapine, olanzapine and clozapine, whereas those with elevated cerebrovascular risk should avoid olanzapine and risperidone [<xref rid='CR47' ref-type='bibr'>47</xref>].</s><s sid='106'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Olanzapine is also associated with motor decline in PD patients with psychosis [<xref rid='CR20' ref-type='bibr'>20</xref>].</s><s sid='107'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The Movement Disorders Society advises against olanzapine use in PD [<xref rid='CR20' ref-type='bibr'>20</xref>], advice that might reasonably be extended to DLB patients.</s><s sid='108'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Irrespective of which antipsychotic medication is used, prescribers should be wary of the cardiac denervation seen in the synucleinopathies [<xref rid='CR22' ref-type='bibr'>22</xref>] and so consider monitoring the QT interval.</s><s sid='109'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This is especially important when cholinesterase inhibitor and neuroleptic medications are used together.</s><s sid='110'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Fortunately, several new agents without such side effects are under development.</s><s sid='111'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> For example, a recent trial of pimavanserin, a selective serotonin 5-HT2A inverse agonist, shows great promise in the treatment of PDD, both in terms of treatment response and trial design [<xref rid='CR73' ref-type='bibr'>73</xref>].</s></p></sec><sec id='Sec6'><title>Agitation and behavioral disturbance</title><p><s sid='112'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Agitation and behavioral disturbance often respond to simple measures such as caregiver training, removal of fear triggers, and increased social interaction [<xref rid='CR74' ref-type='bibr'>74</xref>].</s><s sid='113'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Many triggers for agitation are fleeting, and episodes of agitation are self-limiting, so watchful waiting is often preferable to antipsychotic prescription [<xref rid='CR53' ref-type='bibr'>53</xref>].</s><s sid='114'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> In the late stages of disease, when patients have difficulty expressing their needs, pain is often a trigger for agitation: investigation for potential sources of pain and empiric treatment with simple analgesics such as acetaminophen should be first-line therapy [<xref rid='CR75' ref-type='bibr'>75</xref>].</s><s sid='115'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Antipsychotic medications have the same qualifications to their use as noted above.</s><s sid='116'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Furthermore, behavioral disturbances such as sleep–wake cycle disturbance, shouting, oppositional behavior, pacing, agitation, and aggression are not good targets of therapy for the neuroleptic medications.</s><s sid='117'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> There are numerous carer training programs designed to decrease the disturbances, but only six medications have evidence for efficacy, three of which are readily accessible [<xref rid='CR76' ref-type='bibr'>76</xref>–<xref rid='CR78' ref-type='bibr'>78</xref>].</s><s sid='118'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Successful programs train caregivers to understand care situations from the perspective of people with moderate to severe dementia, and to adapt their approach to such encounters to encourage respect for the patient’s personhood [<xref rid='CR55' ref-type='bibr'>55</xref>].</s><s sid='119'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Extensive training is required for program success [<xref rid='CR76' ref-type='bibr'>76</xref>–<xref rid='CR78' ref-type='bibr'>78</xref>].</s></p></sec></sec><sec id='Sec7'><title>Movement symptoms</title><p><s sid='120'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The motor symptoms and signs of DLB are similar to those found in PD, including rigidity, bradykinesia, tremor, and gait difficulties.</s><s sid='121'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> They may respond to physical therapy and home safety modification.</s><s sid='122'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> As is the case in PD, the primary prevention of falls is paramount in DLB.</s><s sid='123'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Education on the importance of this point can be punctuated with advice such as ‘gravity is your mortal enemy’.</s><s sid='124'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Repeated falls should trigger a rapid assessment and treatment of the cause(s).</s></p><p><s sid='125'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The same medications that are used in PD for movement symptoms are used in DLB, but they are usually less effective than in PD [<xref rid='CR79' ref-type='bibr'>79</xref>].</s><s sid='126'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Their use is often limited because of their tendency to exacerbate the neuropsychiatric features of DLB [<xref rid='CR79' ref-type='bibr'>79</xref>–<xref rid='CR81' ref-type='bibr'>81</xref>].</s><s sid='127'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Levodopa/carbidopa is most useful in patients with prominent parkinsonism and few or no neuropsychiatric symptoms [<xref rid='CR81' ref-type='bibr'>81</xref>].</s><s sid='128'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Levodopa/carbidopa is used in preference to the dopamine agonists because the latter are more likely to induce compulsive behavior.</s><s sid='129'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In one series, 24 % of PD patients taking dopamine agonists suffered from this potentially devastating constellation of side effects [<xref rid='CR82' ref-type='bibr'>82</xref>].</s><s sid='130'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Amantadine may reduce the severity of the compulsive behaviors, but can also worsen dysautonomia and hallucinations [<xref rid='CR20' ref-type='bibr'>20</xref>].</s></p><p><s sid='131'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Physical therapy and home modification are effective in PD.</s><s sid='132'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Cholinesterase inhibitors may exacerbate tremor, but only mildly so, and do not otherwise worsen parkinsonism [<xref rid='CR26' ref-type='bibr'>26</xref>, <xref rid='CR39' ref-type='bibr'>39</xref>].</s><s sid='133'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Where possible, medications that can induce parkinsonism should be avoided – these include the dopamine receptor blocking anti-emetics (for example, prochlorperazine and metoclopramide) and neuroleptics.</s></p></sec><sec id='Sec8'><title>Autonomic symptoms</title><sec id='Sec9'><title>Constipation</title><p><s sid='134'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The most common autonomic complications of synucleinopathy are under-recognized: 89 % of PD patients have constipation or diarrhea.</s><s sid='135'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Sixteen percent of the patients have been hospitalized for bowel obstruction [<xref rid='CR24' ref-type='bibr'>24</xref>, <xref rid='CR25' ref-type='bibr'>25</xref>].</s><s sid='136'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Patients may be unaware that this is a consequence of their DLB, since the symptoms usually predate other aspects of the syndrome by many years [<xref rid='CR10' ref-type='bibr'>10</xref>, <xref rid='CR21' ref-type='bibr'>21</xref>, <xref rid='CR34' ref-type='bibr'>34</xref>].</s><s sid='137'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Directed questions and early treatment with a high-fiber diet, exercise, stool softeners, psyllium [<xref rid='CR83' ref-type='bibr'>83</xref>], polyethylene glycol [<xref rid='CR84' ref-type='bibr'>84</xref>], methylcellulose, docusate, and misoprostol [<xref rid='CR49' ref-type='bibr'>49</xref>] are effective.</s><s sid='138'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Increased bowel activity is a common (and in this case welcome) side effect of cholinesterase inhibitor therapy.</s></p></sec><sec id='Sec10'><title>Genitourinary symptoms</title><p><s sid='139'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Up to 83 % of PD patients experience urinary frequency, urgency, and incontinence [<xref rid='CR85' ref-type='bibr'>85</xref>], for which oral trospium and transdermal oxybutyinin are effective [<xref rid='CR20' ref-type='bibr'>20</xref>] alternatives to trihexyphenidyl and oral oxybutyinin, which cause confusion [<xref rid='CR8' ref-type='bibr'>8</xref>, <xref rid='CR86' ref-type='bibr'>86</xref>–<xref rid='CR88' ref-type='bibr'>88</xref>].</s><s sid='140'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Tamsulosin and bethanol chloride are effective for prostatism and urinary retention [<xref rid='CR49' ref-type='bibr'>49</xref>].</s><s sid='141'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Sildenafil is effective for erectile dysfunction in PD [<xref rid='CR89' ref-type='bibr'>89</xref>], but prescription requests should trigger a review to determine whether levodopa or dopamine agonist treatment is inducing hypersexual behavior [<xref rid='CR82' ref-type='bibr'>82</xref>, <xref rid='CR85' ref-type='bibr'>85</xref>].</s></p></sec><sec id='Sec11'><title>Postural hypotension</title><p><s sid='142'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Orthostatic symptoms are common in DLB [<xref rid='CR58' ref-type='bibr'>58</xref>, <xref rid='CR90' ref-type='bibr'>90</xref>]; their frequency and severity is a strong predictor of prognosis [<xref rid='CR91' ref-type='bibr'>91</xref>].</s><s sid='143'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Patients may not describe classic postural symptoms, but instead mention nonspecific weakness or lethargy.</s><s sid='144'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Reduction or cessation of antihypertensive medication, meal fragmentation, salt liberalization/supplementation and compression stockings [<xref rid='CR20' ref-type='bibr'>20</xref>], fludrocortisone [<xref rid='CR92' ref-type='bibr'>92</xref>], and domperidone [<xref rid='CR92' ref-type='bibr'>92</xref>] are all effective in the synucleinopathies.</s><s sid='145'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Cholinesterase inhibition [<xref rid='CR93' ref-type='bibr'>93</xref>] and pyrodostigmine [<xref rid='CR94' ref-type='bibr'>94</xref>] also improve these symptoms.</s></p></sec></sec><sec id='Sec12'><title>Sleep symptoms</title><sec id='Sec13'><title>Excessive daytime sleepiness</title><p><s sid='146'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>It is easy to underestimate the effect that excessive sleepiness can have on a patient’s quality of life.</s><s sid='147'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Sedating medications should be ceased and obstructive sleep apnea, primary sleep disorders, and nocturia should be ruled out.</s><s sid='148'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Caffeine is a useful treatment in those without periodic leg movement disorder of sleep or restless leg syndrome [<xref rid='CR95' ref-type='bibr'>95</xref>].</s><s sid='149'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The evidence for methylphenidate and dextroamphetamine is mixed [<xref rid='CR20' ref-type='bibr'>20</xref>].</s><s sid='150'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Modafinil was effective in two of three PD trials [<xref rid='CR20' ref-type='bibr'>20</xref>, <xref rid='CR96' ref-type='bibr'>96</xref>].</s><s sid='151'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Eighteen of 20 patients responded well in a small, unblinded trial of armodafinil [<xref rid='CR97' ref-type='bibr'>97</xref>].</s></p></sec><sec id='Sec14'><title>Rapid eye movement sleep behavior disorder</title><p><s sid='152'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Seventy-six percent of DLB patients act out their dreams [<xref rid='CR98' ref-type='bibr'>98</xref>].</s><s sid='153'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> When confirmed by polysomnography, rapid eye movement sleep behavior disorder is 98 % specific to the disorders of synuclein [<xref rid='CR99' ref-type='bibr'>99</xref>].</s><s sid='154'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The disorder may not require treatment unless it induces excessive daytime sleepiness, or poses a physical risk to the patient or their bed partner.</s><s sid='155'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Simple instructions can prevent harm: remove sharp objects from the bedside, use soft barriers around the bed, or sleep in a tightly closed sleeping bag (cocooning) [<xref rid='CR95' ref-type='bibr'>95</xref>, <xref rid='CR100' ref-type='bibr'>100</xref>].</s><s sid='156'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The enacted dream often involves being chased or attacked, so bed partners should avoid the dreamer lest they be incorporated into the dream and attacked [<xref rid='CR95' ref-type='bibr'>95</xref>].</s><s sid='157'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Randomized controlled trials demonstrate that melatonin [<xref rid='CR101' ref-type='bibr'>101</xref>–<xref rid='CR103' ref-type='bibr'>103</xref>], rivastigmine [<xref rid='CR104' ref-type='bibr'>104</xref>], and bed alarms that play soothing messages from caregivers [<xref rid='CR100' ref-type='bibr'>100</xref>] are effective rapid eye movement sleep behavior disorder treatments.</s><s sid='158'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The short half-life of melatonin means that a second dose may be needed if sleep is interrupted.</s><s sid='159'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Low-dose clonazepam is a recommended second-line therapy [<xref rid='CR105' ref-type='bibr'>105</xref>].</s></p></sec><sec id='Sec15'><title>Restless leg syndrome and periodic limb movement disorder</title><p><s sid='160'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>These conditions often accompany the disorders of synuclein, and each other [<xref rid='CR106' ref-type='bibr'>106</xref>].</s><s sid='161'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The treatment options are identical for the two disorders; however, periodic limb movement disorder does not require treatment unless it is disrupting sleep or sleep architecture.</s><s sid='162'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> There are no trials of restless leg syndrome or periodic limb movement disorder treatment in the context of DLB.</s><s sid='163'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The dopamine agonists are not recommended in this setting for the reasons outlined earlier.</s><s sid='164'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Standard treatment of restless leg syndrome and limb movement disorder with carbidopa/levodopa, benzodiazepines (and especially clonazepam), and the alpha-2-delta calcium channel ligands (gabapentin, gabapentin enacarbil, and pregabalin) are effective in PD patients [<xref rid='CR106' ref-type='bibr'>106</xref>].</s></p></sec></sec><sec sec-type='conclusion' id='Sec16'><title>Conclusions</title><p><s sid='165'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>DLB is a complex disease with many challenging treatment decisions.</s><s sid='166'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> It is often under-recognized in the clinic, in part because the core clinical diagnostic features – fluctuations in cognition, visual hallucinations, and parkinsonism – are nonspecific and subject to varied interpretation.</s><s sid='167'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> For example, how much parkinsonism is enough to qualify for this feature?</s><s sid='168'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Treatment options can improve quality of life, but do not alter the course of the disease.</s><s sid='169'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> For many symptoms, the best treatments are nondrug treatments.</s><s sid='170'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Regular reviews aimed at rationalizing therapy can be beneficial.</s><s sid='171'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> For example, anti-hypertensive medications that were erstwhile well tolerated may induce postural dizziness because alpha-synucleinopathy weakens neurovascular tone.</s><s sid='172'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The most difficult decision relates to the use of antipsychotic medications; these occasionally benefit patients with hallucinations and delusions, but severe reactions such as prolonged rigidity and decreased responsiveness are common in DLB.</s><s sid='173'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Recent trials of antipsychotics with novel mechanisms of action hold promise for this vulnerable population.</s></p></sec><sec sec-type='box' id='Sec17'><title>Note</title><p> This article is part of a series on <italic>Lewy Body Dementia</italic>, edited by Ian McKeith and James Galvin. Other articles in this series can be found at <ext-link ext-link-type='uri' xlink:href='http://alzres.com/series/LewyBodyDementia'>http://alzres.com/series/LewyBodyDementia</ext-link></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>DLB</term><def><p>dementia with Lewy bodies</p></def></def-item><def-item><term>PD</term><def><p>Parkinson’s disease</p></def></def-item><def-item><term>PDD</term><def><p>Parkinson’s disease dementia</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>BPB receives funding from the Michael J Fox Foundation and the Parkinson’s Disease Research Foundation, has served as an investigator for clinical trials sponsored by Pfizer, Janssen, Avid, and Bristol-Myers Squibb, and is an employee of Biogen Idec.</p></fn></fn-group><ref-list id='Bib1'><title>References</title><ref id='CR1'><label>1.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Nelson</surname><given-names>PT</given-names></name><name><surname>Jicha</surname><given-names>GA</given-names></name><name><surname>Kryscio</surname><given-names>RJ</given-names></name><name><surname>Abner</surname><given-names>EL</given-names></name><name><surname>Schmitt</surname><given-names>FA</given-names></name><name><surname>Cooper</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Low sensitivity in clinical diagnoses of dementia with Lewy bodies</article-title><source>J Neurol.</source><year>2010</year><volume>257</volume><fpage>359</fpage><lpage>66</lpage><pub-id pub-id-type='doi'>10.1007/s00415-009-5324-y</pub-id><pub-id pub-id-type='pmid'>19795154</pub-id></element-citation></ref><ref id='CR2'><label>2.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Vann Jones</surname><given-names>SA</given-names></name><name><surname>O'Brien</surname><given-names>JT</given-names></name></person-group><article-title>The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies</article-title><source>Psychol Med.</source><year>2013</year><volume>44</volume><fpage>673</fpage><lpage>83</lpage><pub-id pub-id-type='doi'>10.1017/S0033291713000494</pub-id><pub-id pub-id-type='pmid'>23521899</pub-id></element-citation></ref><ref id='CR3'><label>3.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Boot</surname><given-names>B</given-names></name></person-group><article-title>The incidence and prevalence of dementia with Lewy bodies is underestimated</article-title><source>Psychol Med.</source><year>2013</year><volume>43</volume><fpage>2687</fpage><lpage>8</lpage><pub-id pub-id-type='doi'>10.1017/S0033291713002213</pub-id><pub-id pub-id-type='pmid'>23985217</pub-id></element-citation></ref><ref id='CR4'><label>4.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Lowe</surname><given-names>J</given-names></name><name><surname>Emre</surname><given-names>M</given-names></name><name><surname>O'Brien</surname><given-names>JT</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium</article-title><source>Neurology.</source><year>2005</year><volume>65</volume><fpage>1863</fpage><lpage>72</lpage><pub-id pub-id-type='doi'>10.1212/01.wnl.0000187889.17253.b1</pub-id><pub-id pub-id-type='pmid'>16237129</pub-id></element-citation></ref><ref id='CR5'><label>5.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Francis</surname><given-names>P</given-names></name><name><surname>Corbett</surname><given-names>A</given-names></name></person-group><article-title>Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management</article-title><source>Drugs Aging.</source><year>2013</year><volume>30</volume><fpage>603</fpage><lpage>11</lpage><pub-id pub-id-type='doi'>10.1007/s40266-013-0092-x</pub-id><pub-id pub-id-type='pmid'>23681401</pub-id></element-citation></ref><ref id='CR6'><label>6.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Zaccai</surname><given-names>J</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name></person-group><article-title>A systematic review of prevalence studies of dementia in Parkinson's disease</article-title><source>Mov Disord.</source><year>2005</year><volume>20</volume><fpage>1255</fpage><lpage>63</lpage><pub-id pub-id-type='doi'>10.1002/mds.20527</pub-id><pub-id pub-id-type='pmid'>16041803</pub-id></element-citation></ref><ref id='CR7'><label>7.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Arvanitakis</surname><given-names>Z</given-names></name><name><surname>Bang</surname><given-names>W</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name></person-group><article-title>Mixed brain pathologies account for most dementia cases in community-dwelling older persons</article-title><source>Neurology.</source><year>2007</year><volume>69</volume><fpage>2197</fpage><lpage>204</lpage><pub-id pub-id-type='doi'>10.1212/01.wnl.0000271090.28148.24</pub-id><pub-id pub-id-type='pmid'>17568013</pub-id></element-citation></ref><ref id='CR8'><label>8.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Holmes</surname><given-names>C</given-names></name><name><surname>McKeith</surname><given-names>I</given-names></name><name><surname>Neill</surname><given-names>D</given-names></name><name><surname>O'Brien</surname><given-names>J</given-names></name><name><surname>Cairns</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease</article-title><source>Am J Psychiatry.</source><year>1999</year><volume>156</volume><fpage>1039</fpage><lpage>45</lpage><pub-id pub-id-type='pmid'>10401449</pub-id></element-citation></ref><ref id='CR9'><label>9.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>O'Brien</surname><given-names>J</given-names></name><name><surname>Gray</surname><given-names>A</given-names></name><name><surname>Cormack</surname><given-names>F</given-names></name><name><surname>Ayre</surname><given-names>G</given-names></name><name><surname>Rowan</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease</article-title><source>Arch Neurol.</source><year>2001</year><volume>58</volume><fpage>977</fpage><lpage>82</lpage><pub-id pub-id-type='doi'>10.1001/archneur.58.6.977</pub-id><pub-id pub-id-type='pmid'>11405813</pub-id></element-citation></ref><ref id='CR10'><label>10.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Boot</surname><given-names>BP</given-names></name><name><surname>Orr</surname><given-names>CF</given-names></name><name><surname>Ahlskog</surname><given-names>JE</given-names></name><name><surname>Ferman</surname><given-names>TJ</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><name><surname>Pankratz</surname><given-names>VS</given-names></name><etal></etal></person-group><article-title>Risk factors for dementia with Lewy bodies: a case–control study</article-title><source>Neurology.</source><year>2013</year><volume>81</volume><fpage>833</fpage><lpage>40</lpage><pub-id pub-id-type='doi'>10.1212/WNL.0b013e3182a2cbd1</pub-id><pub-id pub-id-type='pmid'>23892702</pub-id></element-citation></ref><ref id='CR11'><label>11.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Stubendorff</surname><given-names>K</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name></person-group><article-title>Differences in survival between patients with dementia with Lewy bodies and patients with Alzheimer's disease - measured from a fixed cognitive level</article-title><source>Dement Geriatr Cogn Disord.</source><year>2011</year><volume>32</volume><fpage>408</fpage><lpage>16</lpage><pub-id pub-id-type='doi'>10.1159/000335364</pub-id><pub-id pub-id-type='pmid'>22327504</pub-id></element-citation></ref><ref id='CR12'><label>12.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Mosimann</surname><given-names>UP</given-names></name><name><surname>McKeith</surname><given-names>IG</given-names></name></person-group><article-title>Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies</article-title><source>J Geriatr Psychiatry Neurol.</source><year>2004</year><volume>17</volume><fpage>164</fpage><lpage>71</lpage><pub-id pub-id-type='doi'>10.1177/0891988704267463</pub-id><pub-id pub-id-type='pmid'>15312280</pub-id></element-citation></ref><ref id='CR13'><label>13.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Emre</surname><given-names>M</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Albanese</surname><given-names>A</given-names></name><name><surname>Byrne</surname><given-names>E</given-names></name><name><surname>Deuschl</surname><given-names>G</given-names></name><name><surname>De Deyn</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Rivastigmine for dementia associated with Parkinson's disease</article-title><source>N Engl J Med.</source><year>2004</year><volume>351</volume><fpage>2509</fpage><lpage>18</lpage><pub-id pub-id-type='doi'>10.1056/NEJMoa041470</pub-id><pub-id pub-id-type='pmid'>15590953</pub-id></element-citation></ref><ref id='CR14'><label>14.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Rolinski</surname><given-names>M</given-names></name><name><surname>Fox</surname><given-names>C</given-names></name><name><surname>Maidment</surname><given-names>I</given-names></name><name><surname>McShane</surname><given-names>R</given-names></name></person-group><article-title>Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease</article-title><source>Cochrane Database Syst Rev.</source><year>2012</year><volume>3</volume><fpage>CD006504</fpage><pub-id pub-id-type='pmid'>22419314</pub-id></element-citation></ref><ref id='CR15'><label>15.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Emre</surname><given-names>M</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Lane</surname><given-names>RM</given-names></name></person-group><article-title>Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences</article-title><source>J Alzheimers Dis.</source><year>2007</year><volume>11</volume><fpage>509</fpage><lpage>19</lpage><pub-id pub-id-type='pmid'>17656830</pub-id></element-citation></ref><ref id='CR16'><label>16.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Klein</surname><given-names>JC</given-names></name><name><surname>Eggers</surname><given-names>C</given-names></name><name><surname>Kalbe</surname><given-names>E</given-names></name><name><surname>Weisenbach</surname><given-names>S</given-names></name><name><surname>Hohmann</surname><given-names>C</given-names></name><name><surname>Vollmar</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo</article-title><source>Neurology.</source><year>2010</year><volume>74</volume><fpage>885</fpage><lpage>92</lpage><pub-id pub-id-type='doi'>10.1212/WNL.0b013e3181d55f61</pub-id><pub-id pub-id-type='pmid'>20181924</pub-id></element-citation></ref><ref id='CR17'><label>17.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ferman</surname><given-names>TJ</given-names></name><name><surname>Smith</surname><given-names>GE</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Ivnik</surname><given-names>RJ</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Knopman</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging</article-title><source>Neurology.</source><year>2004</year><volume>62</volume><fpage>181</fpage><lpage>7</lpage><pub-id pub-id-type='doi'>10.1212/WNL.62.2.181</pub-id><pub-id pub-id-type='pmid'>14745051</pub-id></element-citation></ref><ref id='CR18'><label>18.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Mori</surname><given-names>E</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Kosaka</surname><given-names>K</given-names></name></person-group><article-title>Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial</article-title><source>Ann Neurol.</source><year>2012</year><volume>72</volume><fpage>41</fpage><lpage>52</lpage><pub-id pub-id-type='doi'>10.1002/ana.23557</pub-id><pub-id pub-id-type='pmid'>22829268</pub-id></element-citation></ref><ref id='CR19'><label>19.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>E</given-names></name><name><surname>Kosaka</surname><given-names>K</given-names></name><name><surname>Iseki</surname><given-names>E</given-names></name><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Matsukawa</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study</article-title><source>Dement Geriatr Cogn Disord.</source><year>2013</year><volume>36</volume><fpage>229</fpage><lpage>41</lpage><pub-id pub-id-type='doi'>10.1159/000351672</pub-id><pub-id pub-id-type='pmid'>23949147</pub-id></element-citation></ref><ref id='CR20'><label>20.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Weintraub</surname><given-names>D</given-names></name><name><surname>Coelho</surname><given-names>M</given-names></name><name><surname>Perez-Lloret</surname><given-names>S</given-names></name><name><surname>Fox</surname><given-names>SH</given-names></name><name><surname>Katzenschlager</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease</article-title><source>Mov Disord.</source><year>2011</year><volume>26</volume><fpage>S42</fpage><lpage>80</lpage><pub-id pub-id-type='doi'>10.1002/mds.23884</pub-id><pub-id pub-id-type='pmid'>22021174</pub-id></element-citation></ref><ref id='CR21'><label>21.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Gagnon</surname><given-names>JF</given-names></name><name><surname>Pelletier</surname><given-names>A</given-names></name><name><surname>Montplaisir</surname><given-names>J</given-names></name></person-group><article-title>Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies</article-title><source>Mov Disord.</source><year>2013</year><volume>28</volume><fpage>597</fpage><lpage>604</lpage><pub-id pub-id-type='doi'>10.1002/mds.25445</pub-id><pub-id pub-id-type='pmid'>23554107</pub-id></element-citation></ref><ref id='CR22'><label>22.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Treglia</surname><given-names>G</given-names></name><name><surname>Cason</surname><given-names>E</given-names></name><name><surname>Stefanelli</surname><given-names>A</given-names></name><name><surname>Cocciolillo</surname><given-names>F</given-names></name><name><surname>Di Giuda</surname><given-names>D</given-names></name><name><surname>Fagioli</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis</article-title><source>Clin Auton Res.</source><year>2012</year><volume>22</volume><fpage>43</fpage><lpage>55</lpage><pub-id pub-id-type='doi'>10.1007/s10286-011-0135-5</pub-id><pub-id pub-id-type='pmid'>21792729</pub-id></element-citation></ref><ref id='CR23'><label>23.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Rosenbloom</surname><given-names>MH</given-names></name><name><surname>Finley</surname><given-names>R</given-names></name><name><surname>Scheinman</surname><given-names>MM</given-names></name><name><surname>Feldman</surname><given-names>MD</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Rabinovici</surname><given-names>GD</given-names></name></person-group><article-title>Donepezil-associated bradyarrhythmia in a patient with dementia with Lewy bodies (DLB)</article-title><source>Alzheimer Dis Assoc Disord.</source><year>2010</year><volume>24</volume><fpage>209</fpage><lpage>11</lpage><pub-id pub-id-type='doi'>10.1097/WAD.0b013e3181b7642b</pub-id><pub-id pub-id-type='pmid'>20505440</pub-id></element-citation></ref><ref id='CR24'><label>24.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lawrence</surname><given-names>J</given-names></name><name><surname>Parmenter</surname><given-names>T</given-names></name><name><surname>McDonald</surname><given-names>T</given-names></name></person-group><article-title>Failure to manage constipation in Parkinson's disease. A review of medical services: a patients perspective</article-title><source>Movement Disorders</source><year>2013</year><volume>28 Suppl 1</volume><fpage>187</fpage></element-citation></ref><ref id='CR25'><label>25.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Jost</surname><given-names>WH</given-names></name></person-group><article-title>Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management</article-title><source>Drugs Aging</source><year>1997</year><volume>10</volume><fpage>249</fpage><lpage>58</lpage><pub-id pub-id-type='doi'>10.2165/00002512-199710040-00002</pub-id><pub-id pub-id-type='pmid'>9108986</pub-id></element-citation></ref><ref id='CR26'><label>26.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Wesnes</surname><given-names>KA</given-names></name><name><surname>McKeith</surname><given-names>I</given-names></name><name><surname>Edgar</surname><given-names>C</given-names></name><name><surname>Emre</surname><given-names>M</given-names></name><name><surname>Lane</surname><given-names>R</given-names></name></person-group><article-title>Benefits of rivastigmine on attention in dementia associated with Parkinson disease</article-title><source>Neurology.</source><year>2005</year><volume>65</volume><fpage>1654</fpage><lpage>6</lpage><pub-id pub-id-type='doi'>10.1212/01.wnl.0000184517.69816.e9</pub-id><pub-id pub-id-type='pmid'>16301500</pub-id></element-citation></ref><ref id='CR27'><label>27.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Rongve</surname><given-names>A</given-names></name><name><surname>Broadstock</surname><given-names>M</given-names></name><name><surname>Svenningsson</surname><given-names>P</given-names></name></person-group><article-title>Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia</article-title><source>Curr Neurol Neurosci Rep.</source><year>2012</year><volume>12</volume><fpage>492</fpage><lpage>501</lpage><pub-id pub-id-type='doi'>10.1007/s11910-012-0290-7</pub-id><pub-id pub-id-type='pmid'>22806065</pub-id></element-citation></ref><ref id='CR28'><label>28.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Emre</surname><given-names>M</given-names></name><name><surname>Tsolaki</surname><given-names>M</given-names></name><name><surname>Bonuccelli</surname><given-names>U</given-names></name><name><surname>Destee</surname><given-names>A</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name><name><surname>Kutzelnigg</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial</article-title><source>Lancet Neurol.</source><year>2010</year><volume>9</volume><fpage>969</fpage><lpage>77</lpage><pub-id pub-id-type='doi'>10.1016/S1474-4422(10)70194-0</pub-id><pub-id pub-id-type='pmid'>20729148</pub-id></element-citation></ref><ref id='CR29'><label>29.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Weintraub</surname><given-names>D</given-names></name><name><surname>Mavandadi</surname><given-names>S</given-names></name><name><surname>Mamikonyan</surname><given-names>E</given-names></name><name><surname>Siderowf</surname><given-names>AD</given-names></name><name><surname>Duda</surname><given-names>JE</given-names></name><name><surname>Hurtig</surname><given-names>HI</given-names></name><etal></etal></person-group><article-title>Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease</article-title><source>Neurology.</source><year>2010</year><volume>75</volume><fpage>448</fpage><lpage>55</lpage><pub-id pub-id-type='doi'>10.1212/WNL.0b013e3181ebdd79</pub-id><pub-id pub-id-type='pmid'>20679638</pub-id></element-citation></ref><ref id='CR30'><label>30.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Hanagasi</surname><given-names>HA</given-names></name><name><surname>Gurvit</surname><given-names>H</given-names></name><name><surname>Unsalan</surname><given-names>P</given-names></name><name><surname>Horozoglu</surname><given-names>H</given-names></name><name><surname>Tuncer</surname><given-names>N</given-names></name><name><surname>Feyzioglu</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study</article-title><source>Mov Disord.</source><year>2011</year><volume>26</volume><fpage>1851</fpage><lpage>8</lpage><pub-id pub-id-type='doi'>10.1002/mds.23738</pub-id><pub-id pub-id-type='pmid'>21500280</pub-id></element-citation></ref><ref id='CR31'><label>31.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kehagia</surname><given-names>AA</given-names></name><name><surname>Barker</surname><given-names>RA</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name></person-group><article-title>Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease</article-title><source>Lancet Neurol.</source><year>2010</year><volume>9</volume><fpage>1200</fpage><lpage>13</lpage><pub-id pub-id-type='doi'>10.1016/S1474-4422(10)70212-X</pub-id><pub-id pub-id-type='pmid'>20880750</pub-id></element-citation></ref><ref id='CR32'><label>32.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Cooper</surname><given-names>JA</given-names></name><name><surname>Sagar</surname><given-names>HJ</given-names></name><name><surname>Doherty</surname><given-names>SM</given-names></name><name><surname>Jordan</surname><given-names>N</given-names></name><name><surname>Tidswell</surname><given-names>P</given-names></name><name><surname>Sullivan</surname><given-names>EV</given-names></name></person-group><article-title>Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients</article-title><source>Brain</source><year>1992</year><volume>115 Pt 6</volume><fpage>1701</fpage><lpage>25</lpage><pub-id pub-id-type='doi'>10.1093/brain/115.6.1701</pub-id><pub-id pub-id-type='pmid'>1486457</pub-id></element-citation></ref><ref id='CR33'><label>33.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Svenningsson</surname><given-names>P</given-names></name><name><surname>Westman</surname><given-names>E</given-names></name><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name></person-group><article-title>Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment</article-title><source>Lancet Neurol.</source><year>2012</year><volume>11</volume><fpage>697</fpage><lpage>707</lpage><pub-id pub-id-type='doi'>10.1016/S1474-4422(12)70152-7</pub-id><pub-id pub-id-type='pmid'>22814541</pub-id></element-citation></ref><ref id='CR34'><label>34.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Savica</surname><given-names>R</given-names></name><name><surname>Rocca</surname><given-names>WA</given-names></name><name><surname>Ahlskog</surname><given-names>JE</given-names></name></person-group><article-title>When does Parkinson disease start?</article-title><source>Arch Neurol.</source><year>2010</year><volume>67</volume><fpage>798</fpage><lpage>801</lpage><pub-id pub-id-type='doi'>10.1001/archneurol.2010.135</pub-id><pub-id pub-id-type='pmid'>20625084</pub-id></element-citation></ref><ref id='CR35'><label>35.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ohara</surname><given-names>K</given-names></name><name><surname>Kondo</surname><given-names>N</given-names></name><name><surname>Ohara</surname><given-names>K</given-names></name></person-group><article-title>Changes of monoamines in post-mortem brains from patients with diffuse Lewy body disease</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry.</source><year>1998</year><volume>22</volume><fpage>311</fpage><lpage>7</lpage><pub-id pub-id-type='doi'>10.1016/S0278-5846(98)00048-7</pub-id><pub-id pub-id-type='pmid'>9608603</pub-id></element-citation></ref><ref id='CR36'><label>36.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Sharp</surname><given-names>SI</given-names></name><name><surname>Ballard</surname><given-names>CG</given-names></name><name><surname>Ziabreva</surname><given-names>I</given-names></name><name><surname>Piggott</surname><given-names>MA</given-names></name><name><surname>Perry</surname><given-names>RH</given-names></name><name><surname>Perry</surname><given-names>EK</given-names></name><etal></etal></person-group><article-title>Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia</article-title><source>Dement Geriatr Cogn Disord.</source><year>2008</year><volume>26</volume><fpage>330</fpage><lpage>8</lpage><pub-id pub-id-type='doi'>10.1159/000161058</pub-id><pub-id pub-id-type='pmid'>18841018</pub-id></element-citation></ref><ref id='CR37'><label>37.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name><name><surname>Gagnon</surname><given-names>JF</given-names></name><name><surname>Pelletier</surname><given-names>A</given-names></name><name><surname>Montplaisir</surname><given-names>JY</given-names></name></person-group><article-title>How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder</article-title><source>Brain.</source><year>2012</year><volume>135</volume><fpage>1860</fpage><lpage>70</lpage><pub-id pub-id-type='doi'>10.1093/brain/aws093</pub-id><pub-id pub-id-type='pmid'>22561644</pub-id></element-citation></ref><ref id='CR38'><label>38.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lerche</surname><given-names>S</given-names></name><name><surname>Hobert</surname><given-names>M</given-names></name><name><surname>Brockmann</surname><given-names>K</given-names></name><name><surname>Wurster</surname><given-names>I</given-names></name><name><surname>Gaenslen</surname><given-names>A</given-names></name><name><surname>Hasmann</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Mild parkinsonian signs in the elderly - is there an association with PD? Crossectional findings in 992 individuals</article-title><source>PLoS One.</source><year>2014</year><volume>9</volume><fpage>e92878</fpage><pub-id pub-id-type='doi'>10.1371/journal.pone.0092878</pub-id><pub-id pub-id-type='pmid'>24675747</pub-id></element-citation></ref><ref id='CR39'><label>39.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>Ballard</surname><given-names>CG</given-names></name><name><surname>Perry</surname><given-names>RH</given-names></name><name><surname>Ince</surname><given-names>PG</given-names></name><name><surname>O'Brien</surname><given-names>JT</given-names></name><name><surname>Neill</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies</article-title><source>Neurology.</source><year>2000</year><volume>54</volume><fpage>1050</fpage><lpage>8</lpage><pub-id pub-id-type='doi'>10.1212/WNL.54.5.1050</pub-id><pub-id pub-id-type='pmid'>10720273</pub-id></element-citation></ref><ref id='CR40'><label>40.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Street</surname><given-names>J</given-names></name><name><surname>Masterman</surname><given-names>D</given-names></name><name><surname>Clark</surname><given-names>WS</given-names></name></person-group><article-title>Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies</article-title><source>Dement Geriatr Cogn Disord.</source><year>2002</year><volume>13</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type='doi'>10.1159/000048636</pub-id><pub-id pub-id-type='pmid'>11844887</pub-id></element-citation></ref><ref id='CR41'><label>41.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Culo</surname><given-names>S</given-names></name><name><surname>Mulsant</surname><given-names>BH</given-names></name><name><surname>Rosen</surname><given-names>J</given-names></name><name><surname>Mazumdar</surname><given-names>S</given-names></name><name><surname>Blakesley</surname><given-names>RE</given-names></name><name><surname>Houck</surname><given-names>PR</given-names></name><etal></etal></person-group><article-title>Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial</article-title><source>Alzheimer Dis Assoc Disord.</source><year>2010</year><volume>24</volume><fpage>360</fpage><lpage>4</lpage><pub-id pub-id-type='doi'>10.1097/WAD.0b013e3181e6a4d7</pub-id><pub-id pub-id-type='pmid'>20625270</pub-id></element-citation></ref><ref id='CR42'><label>42.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Weintraub</surname><given-names>D</given-names></name><name><surname>Morales</surname><given-names>KH</given-names></name><name><surname>Moberg</surname><given-names>PJ</given-names></name><name><surname>Bilker</surname><given-names>WB</given-names></name><name><surname>Balderston</surname><given-names>C</given-names></name><name><surname>Duda</surname><given-names>JE</given-names></name><etal></etal></person-group><article-title>Antidepressant studies in Parkinson's disease: a review and meta-analysis</article-title><source>Mov Disord.</source><year>2005</year><volume>20</volume><fpage>1161</fpage><lpage>9</lpage><pub-id pub-id-type='doi'>10.1002/mds.20555</pub-id><pub-id pub-id-type='pmid'>15954137</pub-id></element-citation></ref><ref id='CR43'><label>43.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Chung</surname><given-names>TH</given-names></name><name><surname>Deane</surname><given-names>KH</given-names></name><name><surname>Ghazi-Noori</surname><given-names>S</given-names></name><name><surname>Rickards</surname><given-names>H</given-names></name><name><surname>Clarke</surname><given-names>CE</given-names></name></person-group><article-title>Systematic review of antidepressant therapies in Parkinson's disease</article-title><source>Parkinsonism Relat Disord.</source><year>2003</year><volume>10</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type='doi'>10.1016/S1353-8020(03)00108-1</pub-id><pub-id pub-id-type='pmid'>14643994</pub-id></element-citation></ref><ref id='CR44'><label>44.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Mizukami</surname><given-names>K</given-names></name><name><surname>Yasuno</surname><given-names>F</given-names></name><name><surname>Asada</surname><given-names>T</given-names></name></person-group><article-title>Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy</article-title><source>Psychogeriatrics.</source><year>2009</year><volume>9</volume><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type='doi'>10.1111/j.1479-8301.2009.00292.x</pub-id><pub-id pub-id-type='pmid'>19604326</pub-id></element-citation></ref><ref id='CR45'><label>45.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Truong</surname><given-names>DD</given-names></name><name><surname>Bhidayasiri</surname><given-names>R</given-names></name><name><surname>Wolters</surname><given-names>E</given-names></name></person-group><article-title>Management of non-motor symptoms in advanced Parkinson disease</article-title><source>J Neurol Sci.</source><year>2008</year><volume>266</volume><fpage>216</fpage><lpage>28</lpage><pub-id pub-id-type='doi'>10.1016/j.jns.2007.08.015</pub-id><pub-id pub-id-type='pmid'>17804018</pub-id></element-citation></ref><ref id='CR46'><label>46.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ferman</surname><given-names>TJ</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Smith</surname><given-names>GE</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name></person-group><article-title>The phenomenology of psychotic features in dementia with Lewy bodies (DLB) and Alheimer's diesease (AD)</article-title><source>Neurology.</source><year>2005</year><volume>64</volume><fpage>A257</fpage></element-citation></ref><ref id='CR47'><label>47.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Brodaty</surname><given-names>H</given-names></name><name><surname>Grossberg</surname><given-names>G</given-names></name><name><surname>Robert</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Management of behavioral problems in Alzheimer's disease</article-title><source>Int Psychogeriatr.</source><year>2010</year><volume>22</volume><fpage>346</fpage><lpage>72</lpage><pub-id pub-id-type='doi'>10.1017/S1041610209991505</pub-id><pub-id pub-id-type='pmid'>20096151</pub-id></element-citation></ref><ref id='CR48'><label>48.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Uchiyama</surname><given-names>M</given-names></name><name><surname>Nishio</surname><given-names>Y</given-names></name><name><surname>Yokoi</surname><given-names>K</given-names></name><name><surname>Hirayama</surname><given-names>K</given-names></name><name><surname>Imamura</surname><given-names>T</given-names></name><name><surname>Shimomura</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Pareidolias: complex visual illusions in dementia with Lewy bodies</article-title><source>Brain.</source><year>2012</year><volume>135</volume><fpage>2458</fpage><lpage>69</lpage><pub-id pub-id-type='doi'>10.1093/brain/aws126</pub-id><pub-id pub-id-type='pmid'>22649179</pub-id></element-citation></ref><ref id='CR49'><label>49.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Wood</surname><given-names>LD</given-names></name><name><surname>Neumiller</surname><given-names>JJ</given-names></name><name><surname>Setter</surname><given-names>SM</given-names></name><name><surname>Dobbins</surname><given-names>EK</given-names></name></person-group><article-title>Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease</article-title><source>Am J Geriatr Pharmacother.</source><year>2010</year><volume>8</volume><fpage>294</fpage><lpage>315</lpage><pub-id pub-id-type='doi'>10.1016/j.amjopharm.2010.08.002</pub-id><pub-id pub-id-type='pmid'>20869620</pub-id></element-citation></ref><ref id='CR50'><label>50.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Schneider</surname><given-names>LS</given-names></name><name><surname>Dagerman</surname><given-names>K</given-names></name><name><surname>Insel</surname><given-names>PS</given-names></name></person-group><article-title>Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials</article-title><source>Am J Geriatr Psychiatry.</source><year>2006</year><volume>14</volume><fpage>191</fpage><lpage>210</lpage><pub-id pub-id-type='doi'>10.1097/01.JGP.0000200589.01396.6d</pub-id><pub-id pub-id-type='pmid'>16505124</pub-id></element-citation></ref><ref id='CR51'><label>51.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Powell</surname><given-names>I</given-names></name><name><surname>James</surname><given-names>I</given-names></name><name><surname>Reichelt</surname><given-names>K</given-names></name><name><surname>Myint</surname><given-names>P</given-names></name><name><surname>Potkins</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities</article-title><source>Int J Geriatr Psychiatry.</source><year>2002</year><volume>17</volume><fpage>140</fpage><lpage>5</lpage><pub-id pub-id-type='doi'>10.1002/gps.543</pub-id><pub-id pub-id-type='pmid'>11813276</pub-id></element-citation></ref><ref id='CR52'><label>52.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Musicco</surname><given-names>M</given-names></name><name><surname>Palmer</surname><given-names>K</given-names></name><name><surname>Russo</surname><given-names>A</given-names></name><name><surname>Caltagirone</surname><given-names>C</given-names></name><name><surname>Adorni</surname><given-names>F</given-names></name><name><surname>Pettenati</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer's disease</article-title><source>Dement Geriatr Cogn Disord.</source><year>2011</year><volume>31</volume><fpage>218</fpage><lpage>24</lpage><pub-id pub-id-type='doi'>10.1159/000326213</pub-id><pub-id pub-id-type='pmid'>21474930</pub-id></element-citation></ref><ref id='CR53'><label>53.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Hanney</surname><given-names>ML</given-names></name><name><surname>Theodoulou</surname><given-names>M</given-names></name><name><surname>Douglas</surname><given-names>S</given-names></name><name><surname>McShane</surname><given-names>R</given-names></name><name><surname>Kossakowski</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial</article-title><source>Lancet Neurol.</source><year>2009</year><volume>8</volume><fpage>151</fpage><lpage>7</lpage><pub-id pub-id-type='doi'>10.1016/S1474-4422(08)70295-3</pub-id><pub-id pub-id-type='pmid'>19138567</pub-id></element-citation></ref><ref id='CR54'><label>54.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Brodaty</surname><given-names>H</given-names></name><name><surname>Arasaratnam</surname><given-names>C</given-names></name></person-group><article-title>Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia</article-title><source>Am J Psychiatry.</source><year>2012</year><volume>169</volume><fpage>946</fpage><lpage>53</lpage><pub-id pub-id-type='doi'>10.1176/appi.ajp.2012.11101529</pub-id><pub-id pub-id-type='pmid'>22952073</pub-id></element-citation></ref><ref id='CR55'><label>55.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Gitlin</surname><given-names>LN</given-names></name><name><surname>Kales</surname><given-names>HC</given-names></name><name><surname>Lyketsos</surname><given-names>CG</given-names></name></person-group><article-title>Nonpharmacologic management of behavioral symptoms in dementia</article-title><source>JAMA.</source><year>2012</year><volume>308</volume><fpage>2020</fpage><lpage>9</lpage><pub-id pub-id-type='doi'>10.1001/jama.2012.36918</pub-id><pub-id pub-id-type='pmid'>23168825</pub-id></element-citation></ref><ref id='CR56'><label>56.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ballard</surname><given-names>CG</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Fossey</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>L</given-names></name><name><surname>Jacoby</surname><given-names>R</given-names></name><name><surname>Lana</surname><given-names>MM</given-names></name><etal></etal></person-group><article-title>A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome</article-title><source>J Clin Psychiatry.</source><year>2004</year><volume>65</volume><fpage>114</fpage><lpage>9</lpage><pub-id pub-id-type='doi'>10.4088/JCP.v65n0120</pub-id><pub-id pub-id-type='pmid'>14744180</pub-id></element-citation></ref><ref id='CR57'><label>57.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Perry</surname><given-names>R</given-names></name><name><surname>Larsen</surname><given-names>JP</given-names></name><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>O'Brien</surname><given-names>JT</given-names></name><name><surname>Perry</surname><given-names>EK</given-names></name><etal></etal></person-group><article-title>Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias</article-title><source>J Clin Psychiatry.</source><year>2005</year><volume>66</volume><fpage>633</fpage><lpage>7</lpage><pub-id pub-id-type='doi'>10.4088/JCP.v66n0514</pub-id><pub-id pub-id-type='pmid'>15889951</pub-id></element-citation></ref><ref id='CR58'><label>58.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Howard</surname><given-names>R</given-names></name></person-group><article-title>Neuroleptic drugs in dementia: benefits and harm</article-title><source>Nat Rev Neurosci.</source><year>2006</year><volume>7</volume><fpage>492</fpage><lpage>500</lpage><pub-id pub-id-type='doi'>10.1038/nrn1926</pub-id><pub-id pub-id-type='pmid'>16715057</pub-id></element-citation></ref><ref id='CR59'><label>59.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Rochon</surname><given-names>PA</given-names></name><name><surname>Stukel</surname><given-names>TA</given-names></name><name><surname>Sykora</surname><given-names>K</given-names></name><name><surname>Gill</surname><given-names>S</given-names></name><name><surname>Garfinkel</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>GM</given-names></name><etal></etal></person-group><article-title>Atypical antipsychotics and parkinsonism</article-title><source>Arch Intern Med.</source><year>2005</year><volume>165</volume><fpage>1882</fpage><lpage>8</lpage><pub-id pub-id-type='doi'>10.1001/archinte.165.16.1882</pub-id><pub-id pub-id-type='pmid'>16157833</pub-id></element-citation></ref><ref id='CR60'><label>60.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Hassan</surname><given-names>I</given-names></name></person-group><article-title>Consultation-liaison psychiatry and prevention of severe neuroleptic sensitivity reactions in dementia with Lewy bodies</article-title><source>Australas Psychiatry.</source><year>2011</year><volume>19</volume><fpage>536</fpage><lpage>7</lpage><pub-id pub-id-type='doi'>10.3109/10398562.2011.580750</pub-id><pub-id pub-id-type='pmid'>22077306</pub-id></element-citation></ref><ref id='CR61'><label>61.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Fernandez</surname><given-names>HH</given-names></name><name><surname>Trieschmann</surname><given-names>ME</given-names></name><name><surname>Burke</surname><given-names>MA</given-names></name><name><surname>Friedman</surname><given-names>JH</given-names></name></person-group><article-title>Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies</article-title><source>J Clin Psychiatry.</source><year>2002</year><volume>63</volume><fpage>513</fpage><lpage>5</lpage><pub-id pub-id-type='doi'>10.4088/JCP.v63n0608</pub-id><pub-id pub-id-type='pmid'>12088163</pub-id></element-citation></ref><ref id='CR62'><label>62.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kurlan</surname><given-names>R</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Raman</surname><given-names>R</given-names></name><name><surname>Thal</surname><given-names>L</given-names></name><collab>Alzheimer's Disease Cooperative Study G</collab></person-group><article-title>Quetiapine for agitation or psychosis in patients with dementia and parkinsonism</article-title><source>Neurology.</source><year>2007</year><volume>68</volume><fpage>1356</fpage><lpage>63</lpage><pub-id pub-id-type='doi'>10.1212/01.wnl.0000260060.60870.89</pub-id><pub-id pub-id-type='pmid'>17452579</pub-id></element-citation></ref><ref id='CR63'><label>63.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lopez</surname><given-names>O</given-names></name><name><surname>Becker</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Sweet</surname><given-names>R</given-names></name><name><surname>Aizenstein</surname><given-names>H</given-names></name><name><surname>Snitz</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer’s disease</article-title><source>Am J Psychiatry.</source><year>2013</year><volume>170</volume><fpage>1051</fpage><lpage>8</lpage><pub-id pub-id-type='doi'>10.1176/appi.ajp.2013.12081046</pub-id><pub-id pub-id-type='pmid'>23896958</pub-id></element-citation></ref><ref id='CR64'><label>64.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Boot</surname><given-names>BP</given-names></name><name><surname>McDade</surname><given-names>EM</given-names></name><name><surname>McGinnis</surname><given-names>SM</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name></person-group><article-title>Treatment of dementia with lewy bodies</article-title><source>Curr Treat Options Neurol.</source><year>2013</year><volume>15</volume><fpage>738</fpage><lpage>64</lpage><pub-id pub-id-type='doi'>10.1007/s11940-013-0261-6</pub-id><pub-id pub-id-type='pmid'>24222315</pub-id></element-citation></ref><ref id='CR65'><label>65.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Frieling</surname><given-names>H</given-names></name><name><surname>Hillemacher</surname><given-names>T</given-names></name><name><surname>Ziegenbein</surname><given-names>M</given-names></name><name><surname>Neundorfer</surname><given-names>B</given-names></name><name><surname>Bleich</surname><given-names>S</given-names></name></person-group><article-title>Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis</article-title><source>Eur Neuropsychopharmacol.</source><year>2007</year><volume>17</volume><fpage>165</fpage><lpage>71</lpage><pub-id pub-id-type='doi'>10.1016/j.euroneuro.2006.08.007</pub-id><pub-id pub-id-type='pmid'>17070675</pub-id></element-citation></ref><ref id='CR66'><label>66.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Schneider</surname><given-names>L</given-names></name><name><surname>Tariot</surname><given-names>P</given-names></name><name><surname>Dagerman</surname><given-names>K</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name><name><surname>Hsiao</surname><given-names>J</given-names></name><name><surname>Ismail</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease</article-title><source>N Engl J Med.</source><year>2006</year><volume>355</volume><fpage>1525</fpage><lpage>38</lpage><pub-id pub-id-type='doi'>10.1056/NEJMoa061240</pub-id><pub-id pub-id-type='pmid'>17035647</pub-id></element-citation></ref><ref id='CR67'><label>67.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Fernandez</surname><given-names>HH</given-names></name><name><surname>Trieschmann</surname><given-names>ME</given-names></name><name><surname>Burke</surname><given-names>MA</given-names></name><name><surname>Jacques</surname><given-names>C</given-names></name><name><surname>Friedman</surname><given-names>JH</given-names></name></person-group><article-title>Long-term outcome of quetiapine use for psychosis among Parkinsonian patients</article-title><source>Mov Disord.</source><year>2003</year><volume>18</volume><fpage>510</fpage><lpage>4</lpage><pub-id pub-id-type='doi'>10.1002/mds.10374</pub-id><pub-id pub-id-type='pmid'>12722164</pub-id></element-citation></ref><ref id='CR68'><label>68.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Factor</surname><given-names>SA</given-names></name><name><surname>Friedman</surname><given-names>JH</given-names></name><name><surname>Lannon</surname><given-names>MC</given-names></name><name><surname>Oakes</surname><given-names>D</given-names></name><name><surname>Bourgeois</surname><given-names>K</given-names></name></person-group><article-title>Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial</article-title><source>Mov Disord.</source><year>2001</year><volume>16</volume><fpage>135</fpage><lpage>9</lpage><pub-id pub-id-type='doi'>10.1002/1531-8257(200101)16:1&lt;135::AID-MDS1006&gt;3.0.CO;2-Q</pub-id><pub-id pub-id-type='pmid'>11215574</pub-id></element-citation></ref><ref id='CR69'><label>69.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Pollak</surname><given-names>P</given-names></name><name><surname>Tison</surname><given-names>F</given-names></name><name><surname>Rascol</surname><given-names>O</given-names></name><name><surname>Destee</surname><given-names>A</given-names></name><name><surname>Pere</surname><given-names>JJ</given-names></name><name><surname>Senard</surname><given-names>JM</given-names></name><etal></etal></person-group><article-title>Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up</article-title><source>J Neurol Neurosurg Psychiatry.</source><year>2004</year><volume>75</volume><fpage>689</fpage><lpage>95</lpage><pub-id pub-id-type='doi'>10.1136/jnnp.2003.029868</pub-id><pub-id pub-id-type='pmid'>15090561</pub-id></element-citation></ref><ref id='CR70'><label>70.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Morgante</surname><given-names>L</given-names></name><name><surname>Epifanio</surname><given-names>A</given-names></name><name><surname>Spina</surname><given-names>E</given-names></name><name><surname>Zappia</surname><given-names>M</given-names></name><name><surname>Di Rosa</surname><given-names>AE</given-names></name><name><surname>Marconi</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis</article-title><source>Clin Neuropharmacol.</source><year>2004</year><volume>27</volume><fpage>153</fpage><lpage>6</lpage><pub-id pub-id-type='doi'>10.1097/01.wnf.0000136891.17006.ec</pub-id><pub-id pub-id-type='pmid'>15319699</pub-id></element-citation></ref><ref id='CR71'><label>71.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Merims</surname><given-names>D</given-names></name><name><surname>Balas</surname><given-names>M</given-names></name><name><surname>Peretz</surname><given-names>C</given-names></name><name><surname>Shabtai</surname><given-names>H</given-names></name><name><surname>Giladi</surname><given-names>N</given-names></name></person-group><article-title>Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis</article-title><source>Clin Neuropharmacol.</source><year>2006</year><volume>29</volume><fpage>331</fpage><lpage>7</lpage><pub-id pub-id-type='doi'>10.1097/01.WNF.0000236769.31279.19</pub-id><pub-id pub-id-type='pmid'>17095896</pub-id></element-citation></ref><ref id='CR72'><label>72.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Fox</surname><given-names>SH</given-names></name><name><surname>Katzenschlager</surname><given-names>R</given-names></name><name><surname>Lim</surname><given-names>SY</given-names></name><name><surname>Ravina</surname><given-names>B</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Coelho</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease</article-title><source>Mov Disord.</source><year>2011</year><volume>26</volume><fpage>S2</fpage><lpage>41</lpage><pub-id pub-id-type='doi'>10.1002/mds.23829</pub-id><pub-id pub-id-type='pmid'>22021173</pub-id></element-citation></ref><ref id='CR73'><label>73.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Isaacson</surname><given-names>S</given-names></name><name><surname>Mills</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>H</given-names></name><name><surname>Chi-Burris</surname><given-names>K</given-names></name><name><surname>Corbett</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial</article-title><source>Lancet.</source><year>2014</year><volume>383</volume><fpage>533</fpage><lpage>40</lpage><pub-id pub-id-type='doi'>10.1016/S0140-6736(13)62106-6</pub-id><pub-id pub-id-type='pmid'>24183563</pub-id></element-citation></ref><ref id='CR74'><label>74.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Rhodes-Kropf</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Castillo</surname><given-names>EH</given-names></name><name><surname>Fulton</surname><given-names>AT</given-names></name></person-group><article-title>Managing the patient with dementia in long-term care</article-title><source>Clin Geriatr Med.</source><year>2011</year><volume>27</volume><fpage>135</fpage><lpage>52</lpage><pub-id pub-id-type='doi'>10.1016/j.cger.2011.01.001</pub-id><pub-id pub-id-type='pmid'>21641502</pub-id></element-citation></ref><ref id='CR75'><label>75.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Husebo</surname><given-names>BS</given-names></name><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Sandvik</surname><given-names>R</given-names></name><name><surname>Nilsen</surname><given-names>OB</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name></person-group><article-title>Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial</article-title><source>BMJ.</source><year>2011</year><volume>343</volume><fpage>d4065</fpage><pub-id pub-id-type='doi'>10.1136/bmj.d4065</pub-id><pub-id pub-id-type='pmid'>21765198</pub-id></element-citation></ref><ref id='CR76'><label>76.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Fossey</surname><given-names>J</given-names></name><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Juszczak</surname><given-names>E</given-names></name><name><surname>James</surname><given-names>I</given-names></name><name><surname>Alder</surname><given-names>N</given-names></name><name><surname>Jacoby</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial</article-title><source>BMJ.</source><year>2006</year><volume>332</volume><fpage>756</fpage><lpage>61</lpage><pub-id pub-id-type='doi'>10.1136/bmj.38782.575868.7C</pub-id><pub-id pub-id-type='pmid'>16543297</pub-id></element-citation></ref><ref id='CR77'><label>77.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Chenoweth</surname><given-names>L</given-names></name><name><surname>King</surname><given-names>MT</given-names></name><name><surname>Jeon</surname><given-names>YH</given-names></name><name><surname>Brodaty</surname><given-names>H</given-names></name><name><surname>Stein-Parbury</surname><given-names>J</given-names></name><name><surname>Norman</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial</article-title><source>Lancet Neurol.</source><year>2009</year><volume>8</volume><fpage>317</fpage><lpage>25</lpage><pub-id pub-id-type='doi'>10.1016/S1474-4422(09)70045-6</pub-id><pub-id pub-id-type='pmid'>19282246</pub-id></element-citation></ref><ref id='CR78'><label>78.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Brooker</surname><given-names>DJ</given-names></name><name><surname>Argyle</surname><given-names>E</given-names></name><name><surname>Scally</surname><given-names>AJ</given-names></name><name><surname>Clancy</surname><given-names>D</given-names></name></person-group><article-title>The enriched opportunities programme for people with dementia: a cluster-randomised controlled trial in 10 extra care housing schemes</article-title><source>Aging Mental Health.</source><year>2011</year><volume>15</volume><fpage>1008</fpage><lpage>17</lpage><pub-id pub-id-type='doi'>10.1080/13607863.2011.583628</pub-id><pub-id pub-id-type='pmid'>21702705</pub-id></element-citation></ref><ref id='CR79'><label>79.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lucetti</surname><given-names>C</given-names></name><name><surname>Logi</surname><given-names>C</given-names></name><name><surname>Del Dotto</surname><given-names>P</given-names></name><name><surname>Berti</surname><given-names>C</given-names></name><name><surname>Ceravolo</surname><given-names>R</given-names></name><name><surname>Baldacci</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Levodopa response in dementia with lewy bodies: a 1-year follow-up study</article-title><source>Parkinsonism Relat Disord.</source><year>2010</year><volume>16</volume><fpage>522</fpage><lpage>6</lpage><pub-id pub-id-type='doi'>10.1016/j.parkreldis.2010.06.004</pub-id><pub-id pub-id-type='pmid'>20615745</pub-id></element-citation></ref><ref id='CR80'><label>80.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Molloy</surname><given-names>S</given-names></name><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>O'Brien</surname><given-names>JT</given-names></name><name><surname>Burn</surname><given-names>DJ</given-names></name></person-group><article-title>The role of levodopa in the management of dementia with Lewy bodies</article-title><source>J Neurol Neurosurg Psychiatry.</source><year>2005</year><volume>76</volume><fpage>1200</fpage><lpage>3</lpage><pub-id pub-id-type='doi'>10.1136/jnnp.2004.052332</pub-id><pub-id pub-id-type='pmid'>16107351</pub-id></element-citation></ref><ref id='CR81'><label>81.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Goldman</surname><given-names>JG</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Brandabur</surname><given-names>M</given-names></name><name><surname>Sanfilippo</surname><given-names>M</given-names></name><name><surname>Stebbins</surname><given-names>GT</given-names></name></person-group><article-title>Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies</article-title><source>Mov Disord.</source><year>2008</year><volume>23</volume><fpage>2248</fpage><lpage>50</lpage><pub-id pub-id-type='doi'>10.1002/mds.22322</pub-id><pub-id pub-id-type='pmid'>18823039</pub-id></element-citation></ref><ref id='CR82'><label>82.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Hassan</surname><given-names>A</given-names></name><name><surname>Bower</surname><given-names>JH</given-names></name><name><surname>Kumar</surname><given-names>N</given-names></name><name><surname>Matsumoto</surname><given-names>JY</given-names></name><name><surname>Fealey</surname><given-names>RD</given-names></name><name><surname>Josephs</surname><given-names>KA</given-names></name><etal></etal></person-group><article-title>Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies</article-title><source>Parkinsonism Relat Disord.</source><year>2011</year><volume>17</volume><fpage>260</fpage><lpage>4</lpage><pub-id pub-id-type='doi'>10.1016/j.parkreldis.2011.01.009</pub-id><pub-id pub-id-type='pmid'>21310646</pub-id></element-citation></ref><ref id='CR83'><label>83.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ashraf</surname><given-names>W</given-names></name><name><surname>Pfeiffer</surname><given-names>RF</given-names></name><name><surname>Park</surname><given-names>F</given-names></name><name><surname>Lof</surname><given-names>J</given-names></name><name><surname>Quigley</surname><given-names>EM</given-names></name></person-group><article-title>Constipation in Parkinson's disease: objective assessment and response to psyllium</article-title><source>Mov Disord.</source><year>1997</year><volume>12</volume><fpage>946</fpage><lpage>51</lpage><pub-id pub-id-type='doi'>10.1002/mds.870120617</pub-id><pub-id pub-id-type='pmid'>9399219</pub-id></element-citation></ref><ref id='CR84'><label>84.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Zangaglia</surname><given-names>R</given-names></name><name><surname>Martignoni</surname><given-names>E</given-names></name><name><surname>Glorioso</surname><given-names>M</given-names></name><name><surname>Ossola</surname><given-names>M</given-names></name><name><surname>Riboldazzi</surname><given-names>G</given-names></name><name><surname>Calandrella</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study</article-title><source>Mov Disord</source><year>2007</year><volume>22</volume><fpage>1239</fpage><lpage>44</lpage><pub-id pub-id-type='doi'>10.1002/mds.21243</pub-id><pub-id pub-id-type='pmid'>17566120</pub-id></element-citation></ref><ref id='CR85'><label>85.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ziemssen</surname><given-names>T</given-names></name><name><surname>Reichmann</surname><given-names>H</given-names></name></person-group><article-title>Non-motor dysfunction in Parkinson's disease</article-title><source>Parkinsonism Relat Disord.</source><year>2007</year><volume>13</volume><fpage>323</fpage><lpage>32</lpage><pub-id pub-id-type='doi'>10.1016/j.parkreldis.2006.12.014</pub-id><pub-id pub-id-type='pmid'>17349813</pub-id></element-citation></ref><ref id='CR86'><label>86.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kay</surname><given-names>GG</given-names></name><name><surname>Abou-Donia</surname><given-names>MB</given-names></name><name><surname>Messer</surname><given-names>WS</given-names><suffix>Jr</suffix></name><name><surname>Murphy</surname><given-names>DG</given-names></name><name><surname>Tsao</surname><given-names>JW</given-names></name><name><surname>Ouslander</surname><given-names>JG</given-names></name></person-group><article-title>Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients</article-title><source>J Am Geriatr Soc.</source><year>2005</year><volume>53</volume><fpage>2195</fpage><lpage>201</lpage><pub-id pub-id-type='doi'>10.1111/j.1532-5415.2005.00537.x</pub-id><pub-id pub-id-type='pmid'>16398909</pub-id></element-citation></ref><ref id='CR87'><label>87.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Pagoria</surname><given-names>D</given-names></name><name><surname>O'Connor</surname><given-names>RC</given-names></name><name><surname>Guralnick</surname><given-names>ML</given-names></name></person-group><article-title>Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients</article-title><source>Curr Urol Rep.</source><year>2011</year><volume>12</volume><fpage>351</fpage><lpage>7</lpage><pub-id pub-id-type='doi'>10.1007/s11934-011-0198-9</pub-id><pub-id pub-id-type='pmid'>21607875</pub-id></element-citation></ref><ref id='CR88'><label>88.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Todorova</surname><given-names>A</given-names></name><name><surname>Vonderheid-Guth</surname><given-names>B</given-names></name><name><surname>Dimpfel</surname><given-names>W</given-names></name></person-group><article-title>Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system</article-title><source>J Clin Pharmacol.</source><year>2001</year><volume>41</volume><fpage>636</fpage><lpage>44</lpage><pub-id pub-id-type='doi'>10.1177/00912700122010528</pub-id><pub-id pub-id-type='pmid'>11402632</pub-id></element-citation></ref><ref id='CR89'><label>89.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Hussain</surname><given-names>IF</given-names></name><name><surname>Brady</surname><given-names>CM</given-names></name><name><surname>Swinn</surname><given-names>MJ</given-names></name><name><surname>Mathias</surname><given-names>CJ</given-names></name><name><surname>Fowler</surname><given-names>CJ</given-names></name></person-group><article-title>Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension</article-title><source>J Neurol Neurosurg Psychiatry.</source><year>2001</year><volume>71</volume><fpage>371</fpage><lpage>4</lpage><pub-id pub-id-type='doi'>10.1136/jnnp.71.3.371</pub-id><pub-id pub-id-type='pmid'>11511713</pub-id></element-citation></ref><ref id='CR90'><label>90.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Thaisetthawatkul</surname><given-names>P</given-names></name><name><surname>Boeve</surname><given-names>B</given-names></name><name><surname>Benarroch</surname><given-names>E</given-names></name><name><surname>Sandroni</surname><given-names>P</given-names></name><name><surname>Ferman</surname><given-names>T</given-names></name><name><surname>Petersen</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Autonomic dysfunction in dementia with Lewy bodies</article-title><source>Neurology.</source><year>2004</year><volume>62</volume><fpage>1804</fpage><lpage>9</lpage><pub-id pub-id-type='doi'>10.1212/01.WNL.0000125192.69777.6D</pub-id><pub-id pub-id-type='pmid'>15159482</pub-id></element-citation></ref><ref id='CR91'><label>91.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Stubendorff</surname><given-names>K</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name></person-group><article-title>The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia</article-title><source>PLoS One.</source><year>2012</year><volume>7</volume><fpage>e45451</fpage><pub-id pub-id-type='doi'>10.1371/journal.pone.0045451</pub-id><pub-id pub-id-type='pmid'>23049679</pub-id></element-citation></ref><ref id='CR92'><label>92.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Schoffer</surname><given-names>KL</given-names></name><name><surname>Henderson</surname><given-names>RD</given-names></name><name><surname>O'Maley</surname><given-names>K</given-names></name><name><surname>O'Sullivan</surname><given-names>JD</given-names></name></person-group><article-title>Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease</article-title><source>Mov Disord.</source><year>2007</year><volume>22</volume><fpage>1543</fpage><lpage>9</lpage><pub-id pub-id-type='doi'>10.1002/mds.21428</pub-id><pub-id pub-id-type='pmid'>17557339</pub-id></element-citation></ref><ref id='CR93'><label>93.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Singer</surname><given-names>W</given-names></name><name><surname>Opfer-Gehrking</surname><given-names>TL</given-names></name><name><surname>McPhee</surname><given-names>BR</given-names></name><name><surname>Hilz</surname><given-names>MJ</given-names></name><name><surname>Bharucha</surname><given-names>AE</given-names></name><name><surname>Low</surname><given-names>PA</given-names></name></person-group><article-title>Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension</article-title><source>J Neurol Neurosurg Psychiatry.</source><year>2003</year><volume>74</volume><fpage>1294</fpage><lpage>8</lpage><pub-id pub-id-type='doi'>10.1136/jnnp.74.9.1294</pub-id><pub-id pub-id-type='pmid'>12933939</pub-id></element-citation></ref><ref id='CR94'><label>94.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Singer</surname><given-names>W</given-names></name><name><surname>Sandroni</surname><given-names>P</given-names></name><name><surname>Opfer-Gehrking</surname><given-names>TL</given-names></name><name><surname>Suarez</surname><given-names>GA</given-names></name><name><surname>Klein</surname><given-names>CM</given-names></name><name><surname>Hines</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Pyridostigmine treatment trial in neurogenic orthostatic hypotension</article-title><source>Arch Neurol.</source><year>2006</year><volume>63</volume><fpage>513</fpage><lpage>8</lpage><pub-id pub-id-type='doi'>10.1001/archneur.63.4.noc50340</pub-id><pub-id pub-id-type='pmid'>16476804</pub-id></element-citation></ref><ref id='CR95'><label>95.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Malhotra</surname><given-names>R</given-names></name><name><surname>Avidan</surname><given-names>AY</given-names></name></person-group><article-title>Neurodegenerative disease and REM behavior disorder</article-title><source>Curr Treat Options Neurol.</source><year>2012</year><volume>14</volume><fpage>474</fpage><lpage>92</lpage><pub-id pub-id-type='doi'>10.1007/s11940-012-0194-5</pub-id><pub-id pub-id-type='pmid'>22879077</pub-id></element-citation></ref><ref id='CR96'><label>96.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Hogl</surname><given-names>B</given-names></name><name><surname>Saletu</surname><given-names>M</given-names></name><name><surname>Brandauer</surname><given-names>E</given-names></name><name><surname>Glatzl</surname><given-names>S</given-names></name><name><surname>Frauscher</surname><given-names>B</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial</article-title><source>Sleep.</source><year>2002</year><volume>25</volume><fpage>905</fpage><lpage>9</lpage><pub-id pub-id-type='pmid'>12489899</pub-id></element-citation></ref><ref id='CR97'><label>97.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kuntz</surname><given-names>K</given-names></name><name><surname>Boeve</surname><given-names>B</given-names></name><name><surname>Drubach</surname><given-names>D</given-names></name><name><surname>Allen</surname><given-names>L</given-names></name><name><surname>Drubach</surname><given-names>D</given-names></name></person-group><article-title>Safety, tolerability, and efficacy of armodafinil therapy for hypersomnia associated with dementia with Lewy bodies</article-title><source>Neurology.</source><year>2012</year><volume>78</volume><fpage>P04.192</fpage><pub-id pub-id-type='doi'>10.1212/WNL.78.1_MeetingAbstracts.P04.192</pub-id></element-citation></ref><ref id='CR98'><label>98.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ferman</surname><given-names>TJ</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Smith</surname><given-names>GE</given-names></name><name><surname>Lin</surname><given-names>SC</given-names></name><name><surname>Silber</surname><given-names>MH</given-names></name><name><surname>Pedraza</surname><given-names>O</given-names></name><etal></etal></person-group><article-title>Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies</article-title><source>Neurology.</source><year>2011</year><volume>77</volume><fpage>875</fpage><lpage>82</lpage><pub-id pub-id-type='doi'>10.1212/WNL.0b013e31822c9148</pub-id><pub-id pub-id-type='pmid'>21849645</pub-id></element-citation></ref><ref id='CR99'><label>99.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Silber</surname><given-names>MH</given-names></name><name><surname>Ferman</surname><given-names>TJ</given-names></name><name><surname>Lin</surname><given-names>SC</given-names></name><name><surname>Benarroch</surname><given-names>EE</given-names></name><name><surname>Schmeichel</surname><given-names>AM</given-names></name><etal></etal></person-group><article-title>Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder</article-title><source>Sleep Med.</source><year>2013</year><volume>14</volume><fpage>754</fpage><lpage>62</lpage><pub-id pub-id-type='doi'>10.1016/j.sleep.2012.10.015</pub-id><pub-id pub-id-type='pmid'>23474058</pub-id></element-citation></ref><ref id='CR100'><label>100.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Howell</surname><given-names>MJ</given-names></name><name><surname>Arneson</surname><given-names>PA</given-names></name><name><surname>Schenck</surname><given-names>CH</given-names></name></person-group><article-title>A novel therapy for REM sleep behavior disorder (RBD)</article-title><source>J Clin Sleep Med.</source><year>2011</year><volume>7</volume><fpage>639</fpage><lpage>44A</lpage><pub-id pub-id-type='pmid'>22171203</pub-id></element-citation></ref><ref id='CR101'><label>101.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Boeve</surname><given-names>B</given-names></name><name><surname>Silber</surname><given-names>M</given-names></name><name><surname>Ferman</surname><given-names>T</given-names></name></person-group><article-title>Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients</article-title><source>Sleep Med.</source><year>2003</year><volume>4</volume><fpage>281</fpage><lpage>4</lpage><pub-id pub-id-type='doi'>10.1016/S1389-9457(03)00072-8</pub-id><pub-id pub-id-type='pmid'>14592300</pub-id></element-citation></ref><ref id='CR102'><label>102.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Dowling</surname><given-names>GA</given-names></name><name><surname>Mastick</surname><given-names>J</given-names></name><name><surname>Colling</surname><given-names>E</given-names></name><name><surname>Carter</surname><given-names>JH</given-names></name><name><surname>Singer</surname><given-names>CM</given-names></name><name><surname>Aminoff</surname><given-names>MJ</given-names></name></person-group><article-title>Melatonin for sleep disturbances in Parkinson's disease</article-title><source>Sleep Med.</source><year>2005</year><volume>6</volume><fpage>459</fpage><lpage>66</lpage><pub-id pub-id-type='doi'>10.1016/j.sleep.2005.04.004</pub-id><pub-id pub-id-type='pmid'>16084125</pub-id></element-citation></ref><ref id='CR103'><label>103.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Medeiros</surname><given-names>CA</given-names></name><name><surname>De Bruin Carvalhedo</surname><given-names>PF</given-names></name><name><surname>Lopes</surname><given-names>LA</given-names></name><name><surname>Magalhaes</surname><given-names>MC</given-names></name><name><surname>de Lourdes Seabra</surname><given-names>M</given-names></name><name><surname>de Bruin</surname><given-names>VM</given-names></name></person-group><article-title>Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study</article-title><source>J Neurol.</source><year>2007</year><volume>254</volume><fpage>459</fpage><lpage>64</lpage><pub-id pub-id-type='doi'>10.1007/s00415-006-0390-x</pub-id><pub-id pub-id-type='pmid'>17404779</pub-id></element-citation></ref><ref id='CR104'><label>104.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Di Giacopo</surname><given-names>R</given-names></name><name><surname>Fasano</surname><given-names>A</given-names></name><name><surname>Quaranta</surname><given-names>D</given-names></name><name><surname>Della Marca</surname><given-names>G</given-names></name><name><surname>Bove</surname><given-names>F</given-names></name><name><surname>Bentivoglio</surname><given-names>AR</given-names></name></person-group><article-title>Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease</article-title><source>Mov Disord.</source><year>2012</year><volume>27</volume><fpage>559</fpage><lpage>61</lpage><pub-id pub-id-type='doi'>10.1002/mds.24909</pub-id><pub-id pub-id-type='pmid'>22290743</pub-id></element-citation></ref><ref id='CR105'><label>105.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Aurora</surname><given-names>RN</given-names></name><name><surname>Zak</surname><given-names>RS</given-names></name><name><surname>Maganti</surname><given-names>RK</given-names></name><name><surname>Auerbach</surname><given-names>SH</given-names></name><name><surname>Casey</surname><given-names>KR</given-names></name><name><surname>Chowdhuri</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Best practice guide for the treatment of REM sleep behavior disorder (RBD)</article-title><source>J Clin Sleep Med.</source><year>2010</year><volume>6</volume><fpage>85</fpage><lpage>95</lpage><pub-id pub-id-type='pmid'>20191945</pub-id></element-citation></ref><ref id='CR106'><label>106.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Hening</surname><given-names>WA</given-names></name><name><surname>Allen</surname><given-names>RP</given-names></name><name><surname>Earley</surname><given-names>CJ</given-names></name><name><surname>Picchietti</surname><given-names>DL</given-names></name><name><surname>Silber</surname><given-names>MH</given-names></name></person-group><article-title>Restless Legs Syndrome Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder</article-title><source>Sleep.</source><year>2004</year><volume>27</volume><fpage>560</fpage><lpage>83</lpage><pub-id pub-id-type='pmid'>15164915</pub-id></element-citation></ref></ref-list></back></article></PAPER>